Skip to content
Evigrade
CriticalTriptan, selective 5HT1B/1D receptor agonist×Selective irreversible MAO-B inhibitor

Updated · Methodology

Mechanism

At recommended doses, selegiline inhibits monoamine oxidase type B (MAO-B) selectively and irreversibly, and above 10 mg a day it may lose this selectivity (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.4, 5.1 and 5.2). Frovatriptan is a selective agonist of serotonin 5-HT1B and 5-HT1D receptors. CYP1A2 is the main enzyme that metabolises it, and monoamine oxidase plays no part (frovatriptan SmPC, AEMPS, sections 5.1 and 5.2). The selegiline SmPC contraindicates selegiline with serotonin agonists because of the risk of serious interactions that can lead to serotonin syndrome. Frovatriptan is not among the examples, but its own SmPC places it in this class (selegiline SmPC, AEMPS, section 4.5). The Spanish frovatriptan SmPC does not rule out serotonin syndrome or hypertension with monoamine oxidase inhibitors (frovatriptan SmPC, AEMPS, section 4.5). The US label warns that serotonin syndrome may occur, particularly with monoamine oxidase inhibitors (frovatriptan label, US Food and Drug Administration, FDA, section 5.7). The monoamine oxidase type A inhibitor moclobemide did not change the pharmacokinetics of frovatriptan, and the documents contain no studies with selegiline (FDA frovatriptan label, section 12.3).

Symptoms

The documents do not describe how this particular combination presents, but the selegiline summary of product characteristics (SmPC) warns that serious interactions with serotonin agonists can lead to serotonin syndrome (Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Signs of serotonin syndrome include mental status changes (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, high temperature), neuromuscular changes (overactive reflexes, poor coordination), nausea, vomiting and diarrhoea. It usually starts within minutes to hours of a new or higher dose of a serotonergic drug (frovatriptan label, US Food and Drug Administration, FDA, section 5.7). The Spanish frovatriptan SmPC also names a risk of hypertension with monoamine oxidase inhibitors (frovatriptan SmPC, AEMPS, section 4.5). The US label reports rare cases of significant rises in blood pressure with 5-HT1 agonists, up to hypertensive crisis with acute impairment of organ systems (FDA frovatriptan label, section 5.8). Above the recommended 10 mg a day, selegiline may lose its selectivity for monoamine oxidase type B (MAO-B), which raises the risk of hypertension (selegiline SmPC, AEMPS, section 4.4). Frovatriptan itself can cause chest pain and tightness, sometimes intense and spreading to the throat (frovatriptan SmPC, AEMPS, section 4.4).

Management

The combination is contraindicated: do not prescribe frovatriptan to people taking selegiline. The selegiline summary of product characteristics (SmPC) lists serotonin agonists among contraindicated combinations (Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Frovatriptan is not among the examples in that sentence, but its own SmPC describes it as a selective agonist of serotonin 5-HT1B and 5-HT1D receptors (frovatriptan SmPC, AEMPS, section 5.1), so the class contraindication applies to it as well. The frovatriptan documents are softer, but this does not lift the contraindication in the selegiline SmPC. The Spanish frovatriptan SmPC (the Spanish marketing authorisation was revoked in May 2024) lists monoamine oxidase inhibitors among combinations that are not recommended (frovatriptan SmPC, AEMPS, section 4.5). The US Food and Drug Administration (FDA) label does not list monoamine oxidase inhibitors among its contraindications (FDA frovatriptan label, section 4). No document gives an interval between stopping selegiline and the first dose of frovatriptan, or for the opposite switch. Selegiline inhibits monoamine oxidase type B (MAO-B) irreversibly, and after a single 10 mg dose platelet MAO-B activity returns to normal in about 2 weeks (selegiline SmPC, AEMPS, section 5.2). If the two drugs have nevertheless been taken together and serotonin syndrome is suspected, stop frovatriptan (FDA frovatriptan label, section 5.7). Monitor blood pressure during frovatriptan treatment (FDA frovatriptan label, section 5.8). Frovatriptan is contraindicated in severe or moderate hypertension and in uncontrolled mild hypertension (frovatriptan SmPC, AEMPS, section 4.3). If chest pain and tightness suggest cardiac ischaemia, withhold further frovatriptan doses and carry out additional assessment (frovatriptan SmPC, AEMPS, section 4.4).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Frovatriptan

Other interactions with Selegiline